JPWO2021163391A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021163391A5 JPWO2021163391A5 JP2022548585A JP2022548585A JPWO2021163391A5 JP WO2021163391 A5 JPWO2021163391 A5 JP WO2021163391A5 JP 2022548585 A JP2022548585 A JP 2022548585A JP 2022548585 A JP2022548585 A JP 2022548585A JP WO2021163391 A5 JPWO2021163391 A5 JP WO2021163391A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- car
- ccr7
- expressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 160
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 144
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 134
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 67
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 52
- 230000011664 signaling Effects 0.000 claims description 38
- 102100027207 CD27 antigen Human genes 0.000 claims description 24
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 24
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 22
- 230000001086 cytosolic effect Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 14
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 14
- 125000006850 spacer group Chemical group 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 11
- 230000000139 costimulatory effect Effects 0.000 claims description 11
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 7
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 6
- 102100033467 L-selectin Human genes 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 137
- 206010052015 cytokine release syndrome Diseases 0.000 description 16
- 206010044221 Toxic encephalopathy Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000007135 neurotoxicity Effects 0.000 description 11
- 231100000228 neurotoxicity Toxicity 0.000 description 11
- 206010029350 Neurotoxicity Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 108090000672 Annexin A5 Proteins 0.000 description 6
- 102000004121 Annexin A5 Human genes 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975724P | 2020-02-12 | 2020-02-12 | |
| US62/975,724 | 2020-02-12 | ||
| PCT/US2021/017739 WO2021163391A1 (en) | 2020-02-12 | 2021-02-11 | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519098A JP2023519098A (ja) | 2023-05-10 |
| JPWO2021163391A5 true JPWO2021163391A5 (de) | 2024-02-21 |
Family
ID=74860463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548585A Pending JP2023519098A (ja) | 2020-02-12 | 2021-02-11 | Ｃｄ１９指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230190798A1 (de) |
| EP (1) | EP4103204A1 (de) |
| JP (1) | JP2023519098A (de) |
| KR (1) | KR20220152220A (de) |
| CN (1) | CN115768443A (de) |
| AU (1) | AU2021220875A1 (de) |
| BR (1) | BR112022015236A2 (de) |
| CA (1) | CA3169672A1 (de) |
| IL (1) | IL295384A (de) |
| MX (1) | MX2022009832A (de) |
| WO (1) | WO2021163391A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097311A2 (en) * | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Hypoimmunogenic mail cells, methods of making and methods of using same |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| DE3583940D1 (de) | 1984-10-02 | 1991-10-02 | Harry M Meade | Herstellung von streptavidinaehnlichen polypeptiden. |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| EP1553168A3 (de) | 1993-06-04 | 2011-04-06 | The United States of America as represented by The Secretary of The Navy | Verfahren zur selektiven Stimulierung der T-Zellproliferation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| JPH11501008A (ja) | 1995-02-09 | 1999-01-26 | ユニバーシティ オブ ワシントン | 改変−アフィニティーストレプトアビジン |
| US6022951A (en) | 1995-04-11 | 2000-02-08 | Univ Boston | Streptavidin mutants |
| US5801115A (en) | 1995-09-05 | 1998-09-01 | Kataleuna Gmbh | Catalyst composition and methods for using and preparing same |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| ATE186235T1 (de) | 1996-04-24 | 1999-11-15 | Claude Fell | Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| CA2283716A1 (en) | 1997-03-14 | 1998-09-17 | Gabriel O. Reznik | Multiflavor streptavidin |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2000038762A1 (en) | 1998-12-24 | 2000-07-06 | Biosafe S.A. | Blood separation system particularly for concentrating hematopoietic stem cells |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (de) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-spezifische umgezielte immunzellen |
| EP1227321A1 (de) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Funktionelle Reinigung von Antigen spezifischen T Lymphozyten durch Peptide-MHC Multimer Färbung |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| EP1893253B1 (de) | 2005-03-23 | 2010-05-19 | Biosafe S.A. | Integriertes system zum sammeln, bearbeiten und transplantieren von zell-subsets, einschliesslich adulter stammzellen, für die regenerative medizin |
| WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| ES2660180T3 (es) | 2007-12-07 | 2018-03-21 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| KR102243575B1 (ko) | 2010-12-09 | 2021-04-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| PT2734538T (pt) | 2011-07-18 | 2018-08-02 | Iba Gmbh | Processo para corar, de forma reversível, uma célula-alvo |
| CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| ES2774160T3 (es) | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| MX361760B (es) | 2012-05-03 | 2018-12-17 | Hutchinson Fred Cancer Res | Receptores de celulas t con afinidad aumentada y metodos para hacer los mismos. |
| RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
| EP2903637B1 (de) | 2012-10-02 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | Zusammensetzungen und verfahren für die immuntherapie |
| WO2014059188A1 (en) | 2012-10-12 | 2014-04-17 | Sage Science, Inc. | Side-eluting molecular fractionator |
| CA2891820A1 (en) | 2012-11-16 | 2014-05-22 | Iba Gmbh | Streptavidin muteins and methods of using them |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| ES2837856T3 (es) | 2013-12-20 | 2021-07-01 | Hutchinson Fred Cancer Res | Moléculas efectoras quiméricas etiquetadas y receptores de las mismas |
| PT3132247T (pt) | 2014-04-16 | 2021-11-03 | Juno Therapeutics Gmbh | Métodos, kits e aparelho para ampliar uma população de células |
| CN106459917B (zh) | 2014-04-23 | 2021-03-09 | 朱诺治疗学股份有限公司 | 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| CA2964487C (en) | 2014-10-15 | 2024-03-19 | Sage Science, Inc. | Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation |
| BR112017009220B1 (pt) | 2014-11-05 | 2022-04-12 | Juno Therapeutics Inc | Método de transdução de células |
| EP3365453A2 (de) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Verfahren, kits, mittel und vorrichtungen zur transduktion |
| JP6662164B2 (ja) | 2016-04-14 | 2020-03-11 | オムロンヘルスケア株式会社 | 圧脈波検出装置及び生体情報測定装置 |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| WO2018197949A1 (en) | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| EP3630132A1 (de) * | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Erzeugnisse und behandlungsverfahren unter verwendung von adoptiver zelltherapie |
| JP2021510738A (ja) * | 2018-01-15 | 2021-04-30 | ファイザー・インク | ４−１ｂｂと組み合わせたキメラ抗原受容体免疫治療製品の投与方法 |
-
2021
- 2021-02-11 WO PCT/US2021/017739 patent/WO2021163391A1/en unknown
- 2021-02-11 KR KR1020227030939A patent/KR20220152220A/ko unknown
- 2021-02-11 MX MX2022009832A patent/MX2022009832A/es unknown
- 2021-02-11 US US17/799,254 patent/US20230190798A1/en active Pending
- 2021-02-11 IL IL295384A patent/IL295384A/en unknown
- 2021-02-11 CN CN202180027165.6A patent/CN115768443A/zh active Pending
- 2021-02-11 BR BR112022015236A patent/BR112022015236A2/pt unknown
- 2021-02-11 AU AU2021220875A patent/AU2021220875A1/en active Pending
- 2021-02-11 EP EP21710721.8A patent/EP4103204A1/de active Pending
- 2021-02-11 CA CA3169672A patent/CA3169672A1/en active Pending
- 2021-02-11 JP JP2022548585A patent/JP2023519098A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI707950B (zh) | 結合分子和使用彼之方法 | |
| TWI691596B (zh) | 嵌合抗原和ｔ細胞受體及使用方法 | |
| JP2024069310A (ja) | キメラ受容体及びその使用方法 | |
| CN107847587B (zh) | Cd30×cd16抗体与pd-1拮抗剂的联合药物 | |
| JP2024056792A (ja) | Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法 | |
| CA2413866C (en) | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations | |
| TW202011999A (zh) | Dll3 的嵌合受體及其使用方法 | |
| JP2020510657A (ja) | 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ | |
| CN107614522A (zh) | 多特异性免疫调节性抗原结合构建体 | |
| TW202003037A (zh) | 引導及導航控制蛋白及其製備和使用方法 | |
| MX2010010028A (es) | Agente para tratar enfermedad. | |
| CA3107938C (en) | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof | |
| EP1749538A1 (de) | Verfahren zur auslösung der differenzierung von regulatorischen t-zellen und ihrer proliferation mit gpi-anker-protein-agonisten und medizinische zusammensetzung dafür | |
| CN110404061A (zh) | 改进的t细胞治疗方法 | |
| US20060228351A1 (en) | Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor | |
| JPWO2021163391A5 (de) | ||
| IL295384A (en) | Preparations of t cells with a chimeric antigen receptor directed against cd19 and methods and uses thereof | |
| JPWO2021163389A5 (de) | ||
| JP2003102471A (ja) | 調節性ｔ細胞の分化誘導・増殖促進方法 | |
| OA19653A (en) | BCMA binding molecules and methods of use thereof. | |
| OA19499A (en) | Chimeric antigen and T cell receptors and methods of use. |